BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghanemi A, Hu X. Targeting the orexinergic system: Mainly but not only for sleep-wakefulness therapies. Alexandria Journal of Medicine 2015;51:279-86. [DOI: 10.1016/j.ajme.2014.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Giblin KA, Basili D, Afzal AM, Rosenbrier-Ribeiro L, Greene N, Barrett I, Hughes SJ, Bender A. New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets. Chem Res Toxicol 2021;34:438-51. [PMID: 33338378 DOI: 10.1021/acs.chemrestox.0c00311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ghanemi A, Hu X. Elements toward novel therapeutic targeting of the adrenergic system. Neuropeptides 2015;49:25-35. [PMID: 25481798 DOI: 10.1016/j.npep.2014.11.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]